difficult, even with GI endoscopy and histopathologic review of mucosal biopsy specimens. Alternatively, the different phenotypes of CE might reflect a single disease process of increasing severity affecting the intestinal immune system and selectively responsive to different interventions over time. A prevailing hypothesis is that most forms of CE involve a complex interplay among host genetics, the intestinal microenvironment (primarily bacteria and dietary constituents), and the immune system. 6 Accordingly, sequential treatment using specially formulated diets, antimicrobials, and immunosuppressive drugs is the most common strategy used to achieve clinical remission, with a final diagnosis often made in response to treatment, histopathologic evaluation of intestinal biopsy specimens, or both.
Over the past 3 decades, many therapeutic interventions have been developed for CE in dogs and cats, but scientific evidence of efficacy and effectiveness often is lacking or highly variable. Still other published studies are small (and often underpowered), and very few properly designed clinical trials have been performed.
Evidence-based medicine (EBM) has emerged in different veterinary disciplines to aid in clinical decision-making regarding patient care. [7] [8] [9] [10] It has been defined as the integration of the best research evidence with clinical expertise and owner and clinician preferences.
The basic tenet of EBM is that integration of these elements (ie, relevant clinical research, clinical expertise, patient and owner preferences, and available resources) will result in the formation of diagnostic and therapeutic plans that optimize clinical outcome and quality of life.
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The purpose of this narrative review based on an extensive literature search was to examine the evidence regarding clinical efficacy and effectiveness of dietary, drug, and alternative or complementary treatments for inducing remission in dogs and cats with CE. We first performed a structured and reproducible search for RCTs and cohort studies and used expert opinion (Albert E.
Jergens and Kelly Makielski as experienced board-certified internists and Annette O'Connor and Jonah Cullen as clinical epidemiologists)
to identify relevant case series and then evaluated the quality of the intervention using quality of evidence grading guidelines. 12 2 | MATERIALS AND METHODS
| Search strategy
The search strategy was developed to identify veterinary studies that and clinician experts in gastroenterology were consulted to identify additional studies.
| Study selection
For the electronic search, studies that used a comparison group were considered relevant (ie, controlled clinical trials reporting the effect of various treatments on clinical remission, cohort studies, and case-control studies). Studies must also have provided a minimum treatment duration of 14 days, must have contained a description of how clinical remission was defined, and must have included histopathologic confirmation of intestinal inflammation if a diagnosis of IBD was made. A single reviewer (Kelly Makielski) assessed the eligibility of these studies, after a training to ensure high agreement with the expert about relevant studies.
In addition to the structured search, a nonstructured search was conducted for non-peer-reviewed articles (eg, scientific proceedings from major veterinary meetings), review papers, and some expert opinion papers. Two reviewers (Kelly Makielski and Jonah Cullen) independently conducted an initial screen of abstracts for eligibility of these sources and evaluated the full-text articles of identified abstracts for final eligibility. The nonstructured search did not limit relevant studies to those with a comparison group (ie, case series were included).
| Data extraction and quality assessment
For all relevant studies identified by the structured and nonstructured search, 2 reviewers (Kelly Makielski and Albert E. Jergens) performed data extraction and assigned an evidence grade based on the study design. Extracted data included study treatment characteristics, participant characteristics, and outcomes. All studies were evaluated using the quality of evidence grading guidelines, which assign a score defining the strength and quality of the evidence. 12 This tool previously has been applied to establish EBM recommendations regarding veterinary nutrition and nephrology. 8, 11, 12 These guidelines categorize the quality of evidence into grades I-IV, based on the applicability to clinical case management (Table 1) . Grades I and II are evidence of the highest quality, whereas grade IV evidence is of the lowest quality.
The quality and strength of the evidence then can be used to make a recommendation about the use of a specific treatment intervention.
| Summation of evidence
The corresponding author (Albert E. Jergens) compiled the data and summarized the findings by treatment options and evidence grade of the relevant studies. For each treatment, a summary of the findings was provided for the available relevant study by evidence grade. The recommendations were developed based on the opinion of the 2 clinical authors after reviewing the literature (Albert E. Jergens and Kelly Makielski).
3 | RESULTS
| Eligible studies
The combined (structured and nonstructured) search strategy identified 1112 canine and 486 feline citations. The original search was conducted in 2015, and then a second search was performed from NovemberDecember 2016 through March 2017. Figures 1 and 2 show the flowcharts of the selection of retrieved studies from both searches. Thirteen RCTs (11 in dogs, 2 in cats) were considered relevant. For the specific treatments in which few or no RCTs were available, the best available evidence was described, resulting in the description of an additional 9 cohort studies and case series. The quality of these selected studies was moderate (grade III), and clinical outcome was considered impactful because they demonstrated innovative treatment strategies that promoted positive patient outcome.
| Diet as primary and adjuvant treatment for CE
Adverse reactions to food are a common cause for GI signs through immunologic (ie, dietary sensitivity triggered by aberrant immune responses) and nonimmunologic (including food intolerance and dietary indiscretion) mechanisms. 13 Clinical studies attest to the central role that diet plays in management of dogs and cats with CE (Table 2) .
| Grade I evidence studies
In 1 RCT, 26 dogs with small intestinal diarrhea randomized in a 2 : 1 ratio to be fed either a diet containing hydrolyzed soy protein (test diet) or an intestinal diet containing proteins from a variety of sources. 14 Outcome measures included subjective response to treatment, change in body weight, and disease activity using the canine IBD activity index (CIBDAI) score. The short-term (3 months) response was 88% in both groups, however, only 1 in 6 dogs fed the intestinal diet versus 13 of 14 dogs fed the hydrolysate diet maintained clinical remission over a 3-year period. For the final examination (median treatment when fed an antigen-restricted diet of salmon and rice for at least 10 days. 1 The severity of clinical signs was scored by means of CIB-DAI. 5 The CIBDAI score decreased significantly after treatment in both groups (in dogs with FRE, 74% moderate to severe before versus 8% after treatment; in dogs with IBD, 85% moderate to severe before versus 32% after treatment). at 4-8 weeks after discharge than those with ARD, and at 6 months to 1 year after discharge as compared to both ARD and SRD groups.
There was no difference in outcome in dogs with FRE who fed an elimination diet or a hydrolyzed diet.
Another study 2 Food-sensitive cats most commonly showed adverse reactions to beef and cereal grains, including wheat, corn, and barley.
In a separate prospective nonrandomized cohort study, 23 cats with IBD (74%) or FRE (26%) responded completely to an elimination dietary trial alone (FRE) or in combination with PO-administered prednisolone (IBD). 18 Clinical response in affected cats was assessed using a combination of GI signs and laboratory markers (eg, feline CE activity index) to define remission.
| Summary
There is strong evidence from RCTs to support a recommendation to feed elimination diets to dogs and cats with CE (grade I evidence).
Moreover, several other descriptive cohort studies and nonrando- (Table 3) . 21, 22 Although numerous trials report remission with the use of metronidazole in dogs and cats, the antimicrobial often was combined with diet and other drugs (eg, glucocorticoids) confounding interpretation as to what portion of the clinical response was attributable to the antimicrobial alone.
| Grade I evidence studies
Tylosin-responsive diarrhea (TRD) is described in dogs as a form of ARD, which typically affects middle-aged, large-breed dogs causing chronic or intermittent small or large intestinal diarrhea. 3, 22 In 1 RCT, the effect of tylosin was investigated in 71 dogs with histories of intermittent diarrhea previously responsive to tylosin administration. 23 Using a placebo-controlled, randomized, double-blinded study design, dogs were assigned in a 2 : 1 ratio to receive tylosin versus placebo and followed over 2 months. Treatment outcome was evaluated as the mean of fecal consistency scores assigned during the last 3 days of the treatment period. Results indicate that 27 of 61 enrolled dogs developed diarrhea during the study period with a greater percentage (P < .05) of dogs that received tylosin (17/20, 85%) versus placebo (2/7, 29%) having normal fecal consistency at study completion.
Another RCT compared the clinical efficacy of rifaximin (RIF) to metronidazole (MET) for treatment of dogs with CE. 24 All dogs enrolled in the study had chronic GI signs and histopathologic lesions of lymphocytic-plasmacytic intestinal inflammation suggestive of idiopathic IBD. Twenty-four dogs were randomized to receive either RIF (n = 14 dogs) or MET (n = 10 dogs) for 21 days, with changes in disease activity (CIBDAI) and serum C-reactive protein (CRP) concentrations measured at the end of the study period. Remission was Two other RCTs investigated the efficacy of MET in treating dogs with IBD. In separate studies, the combination of MET and prednisone was compared to either prednisone alone or a multi-strain probiotic. 25 In both trials, differences between treatments in the rate of clinical remission (CIBDAI) were not observed. Additional details of these separate trials are included below.
| Grade III evidence studies
In an early descriptive single-group cohort study, the responsiveness of histopathologic GC in 9 dogs (8 Boxer dogs and 1 English Bulldog) treated with enrofloxacin alone or in combination with MET and amoxicillin was evaluated. 26 Clinical signs, including diarrhea, resolved in all 9 dogs within 12 days after beginning enrofloxacin alone or in combination A single study describing long-term outcome of dogs with CE reports successful use of tylosin or MET to treat ARD. (Table 4) . 19 Immunosuppressive drug treatment also may include administration of other drugs, especially when adverse effects of corticosteroids are present or when animals fail to respond adequately to systemic corticosteroids. A separate double-blinded RCT compared budesonide and prednisone for induction therapy of IBD in dogs. 31 Forty dogs with IBD were randomized to receive budesonide or prednisone administered daily for 6 weeks with remission rates (>75% reduction in baseline CIBDAI after treatment) and adverse effects serving as outcome measures. Differences in remission rates were not observed between the treatment groups. The frequency and severity of adverse effects reported by pet owners were similar for the 2 treatment groups.
Although most dogs with IBD respond to immunosuppressive doses of corticosteroids, a subset of animals will not respond initially to induction or will relapse after months of treatment. that failed to respond to glucocorticoid treatment. 34 These dogs underwent the same treatment protocol as described above and were evaluated using similar clinical and histopathologic indices of inflammation. Long-term follow-up showed that 2 of 8 dogs with IBD and 7 of 10 dogs with PLE responded favorably to CsA treatment and were rescued from euthanasia.
| Summary
Several RCTs provide high-quality evidence to support a recommendation to administer glucocorticoids as induction treatment to dogs with idiopathic IBD. Separate trials show that single-drug treatment with prednisone is as efficacious as treatment with budesonide alone or prednisone combined with MET. A single prospective cohort study
indicates that prednisolone treatment is effective in cats with IBD (grade III evidence). 18 Evidence supporting a recommendation for use of CsA in dogs with steroid-refractory IBD is based on several, small descriptive cohort studies (grade III evidence).
| Alternative/complementary therapies as primary and adjuvant treatment for CE
The most commonly prescribed treatments for dogs and cats with CE are directed toward suppressing the overactive immune responses causing chronic GI signs. However, there is an important role for nonimmunosuppressive therapies that may decrease mucosal inflammation, counter microbial dysbiosis, and promote a more favorable risk-benefit profile in patients. 35 This need has prompted clinical evaluation of several alternative/complementary treatments including probiotics, prebiotics, and synbiotics for treatment of CE (Table 5) .
| Grade I evidence studies
Probiotics, defined as bacteria with beneficial effects on the host, have broad appeal to clinicians and clients wishing to use "natural" therapeutic approaches. In an open-label trial, 25 the efficacy of a multi-strain probiotic (VSL#3) was investigated for treatment of IBD in dogs. After IBD diagnosis, 20 dogs were randomized to receive treatment with a multi-strain probiotic (n = 10) or combination drug (prednisone + MET) treatment (n = 10) given daily for 8 weeks. Outcomes included disease activity (CIBDAI score), histologic indices, epi- age of the patient, severity of GI signs, serum albumin and cobalamin concentrations, endoscopic mucosal appearances, and the presence of histopathologic changes, such as the type and magnitude of cellular infiltrate, the presence of mucosal bacteria, and architectural alterations of villus atrophy, ulceration or erosions, lymphangiectasia, or crypt abscesses, or some combination of these. 49, 50 Most clinicians favor treatment trials first, reserving endoscopy or surgery to obtain intestinal biopsy specimens in poor-responder or nonresponder patients and to confirm the presence and severity of intestinal inflammation while eliminating other intestinal disorders such as GI histoplasmosis and lymphoma. 51 In several reports, dogs with FRE were younger than dogs with SRD and most often presented with signs of large bowel disease. 17, 34 They also usually showed low clinical disease activity and normal serum albumin con- There is strong evidence from RCTs to support a recommendation to feed elimination diets to dogs and cats with CE (grade I evidence 71, 73 Successful transplantation of ISCs in experimental colitis models demonstrates that they adhere to and become an integrated part of the epithelium, thereby improving mucosal healing.
Lastly, canine ISCs offer a unique drug screening platform for performing high-throughput efficacy and toxicity studies that translate directly to pharmacologic studies in humans with CE. 73 In summary, there are a few well-designed trials (RCT and others) defining optimal treatment for dogs and cats with CE. Current EBM treatment guidelines for CE are found in Table 6 .
There is decidedly greater EBM data on treatment for CE in dogs (examples of grade I evidence) as compared to cats with CE (no evidence for grade I trials with less robust evidence for therapeutic recommendations). Treatments with the strongest evidence supporting their efficacy should be recommended first with considerations for financial resources and client preferences taken into consideration. As noted by others, it would be erroneous to assume that treatments supported by weaker forms of evidence may not be beneficial in some patients with CE.
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